NEMO: A Novel Prognostic Model of Non-Icans Neurotoxicities Associated with Ciltacabtagene Autoleucel

Key Points

• Neurotoxicity associated with Ciltacabtagene Autoleucel is predicted effectively using the NEMO model.
• The model incorporates biomarkers to enhance prognostic accuracy, demonstrating a significant predictive capability.
• This retrospective analysis evaluates clinical outcomes of patients experiencing neurotoxicities following treatment.
• Improved prognostic tools may enable tailored strategies for managing neurotoxicity, enhancing patient care.